Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Deferred Revenue (2021 - 2025)

Historic Current Deferred Revenue for Ocular Therapeutix (OCUL) over the last 8 years, with Q4 2025 value amounting to $14.0 million.

  • Ocular Therapeutix's Current Deferred Revenue fell 90.6% to $14.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.0 million, marking a year-over-year decrease of 90.6%. This contributed to the annual value of $14.0 million for FY2025, which is 90.6% down from last year.
  • Per Ocular Therapeutix's latest filing, its Current Deferred Revenue stood at $14.0 million for Q4 2025, which was down 90.6% from $14.0 million recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's Current Deferred Revenue peaked at $14.6 million during Q2 2023, and registered a low of $13.0 million during Q4 2021.
  • In the last 5 years, Ocular Therapeutix's Current Deferred Revenue had a median value of $14.1 million in 2022 and averaged $14.1 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Current Deferred Revenue soared by 740.77% in 2022, and later tumbled by 354.97% in 2023.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Current Deferred Revenue stood at $13.0 million in 2021, then increased by 7.41% to $14.0 million in 2022, then increased by 3.06% to $14.4 million in 2023, then dropped by 1.82% to $14.1 million in 2024, then dropped by 0.91% to $14.0 million in 2025.
  • Its last three reported values are $14.0 million in Q4 2025, $14.0 million for Q3 2025, and $14.0 million during Q2 2025.